The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed, and funded by an Alkermes company.
Showing 10 of 103 results
Sort by date:
Descending
Jun 2019
Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder
Journal of the American Psychiatric Nurses Association
AUTHOR(S)
May 2019
Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study
Schizophrenia Research
AUTHOR(S)
Apr 2019
A phase-1 open-label study to evaluate the effects of rifampin on the pharmacokinetics of olanzapine and samidorphan administered in combination in healthy human subjects
Clinical Drug Investigation
AUTHOR(S)
Apr 2019
Effect of food on the pharmacokinetics of a combination of olanzapine and samidorphan
Clinical Pharmacology in Drug Development
AUTHOR(S)
Mar 2019
Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study
Psychiatry Research
AUTHOR(S)
Mar 2019
Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique
Journal of Psychiatric Practice
AUTHOR(S)
Mar 2019
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
American Journal of Psychiatry
AUTHOR(S)
Sep 2018
Pharmacokinetic evaluation of a one-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia
Journal of Clinical Psychopharmacology
AUTHOR(S)
Jul 2018
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
European Journal of Drug Metabolism and Pharmacokinetics
AUTHOR(S)
Jul 2018
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry
Addiction
AUTHOR(S)
